Merck Tightens 2025 Outlook, Boosted by Healthcare & Life Science
Update: 2025-11-13
Description
Merck revises its 2025 financial outlook, expecting sales growth of 3% and profit growth of 5-7%. The company attributes this to strong performance in its Healthcare and Life Science segments, offsetting weaker results in Electronics. The updated forecast includes the impact of acquiring SpringWorks Therapeutics and selling Surface Solutions. In Q3, net sales rose 1% to €5.32 billion, with operating profit up 11.3% to €1.22 billion, boosted by asset sales and other income. Despite this, Merck remains cautious about the unpredictable 2025 environment, anticipating a euro-to-US dollar exchange rate between 1.11 and 1.15.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
